
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : $546.0 million
Deal Type : Agreement
Rgenta & GSK Develop RNA Small Molecule Splice Modulators in Strategic Alliance
Details : Under the agreement, Rgenta will use its proprietary discovery platform to develop novel oral RNA-targeting small molecule splice modulators against multiple targets nominated by GSK for development.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $46.0 million
December 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : $546.0 million
Deal Type : Agreement

Rgenta Doses Patients in Trial For MYB-Targeting Drug in ACC And CRC
Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024

Rgenta Therapeutics Gets IND Clearance for RGT-61159 in ACC and CRC
Details : RGT-61159 is an orally available small molecule designed to specifically modulate splicing of the transcription factor MYB. It is being evaluated for adenoid cystic carcinoma & colorectal cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 10, 2024

Details : RGT-61159 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Adenoid Cystic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : H. Lundbeck AS
Deal Size : $110.0 million
Deal Type : Collaboration
Rgenta Therapeutics Enters into a Collaboration with Lundbeck
Details : Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets. Rgenta will grant Lundbeck license of candidate molecules, which will be developed and commercialized by Lundb...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.0 million
August 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : H. Lundbeck AS
Deal Size : $110.0 million
Deal Type : Collaboration

 Reset All
Reset All